News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
742,557 Results
Type
Article (43831)
Company Profile (318)
Press Release (698395)
Multimedia
Podcasts (116)
Webinars (19)
Section
Business (210997)
Career Advice (2112)
Deals (36761)
Drug Delivery (124)
Drug Development (83426)
Employer Resources (176)
FDA (16832)
Job Trends (15504)
News (357393)
Policy (34134)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2616)
Accelerated approval (34)
Adcomms (26)
Allergies (152)
Alliances (51585)
ALS (175)
Alzheimer's disease (1700)
Antibody-drug conjugate (ADC) (329)
Approvals (17100)
Artificial intelligence (544)
Autoimmune disease (163)
Automation (43)
Bankruptcy (372)
Best Places to Work (11772)
BIOSECURE Act (21)
Biosimilars (199)
Biotechnology (188)
Bladder cancer (160)
Brain cancer (61)
Breast cancer (656)
Cancer (4949)
Cardiovascular disease (422)
Career advice (1791)
Career pathing (37)
CAR-T (288)
CDC (50)
Celiac Disease (2)
Cell therapy (764)
Cervical cancer (37)
Clinical research (71225)
Collaboration (1782)
Company closure (4)
Compensation (1188)
Complete response letters (65)
COVID-19 (2788)
CRISPR (99)
C-suite (893)
Cystic fibrosis (148)
Data (6361)
Decentralized trials (2)
Denatured (36)
Depression (138)
Diabetes (510)
Diagnostics (6798)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (265)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (236)
Earnings (92003)
Editorial (61)
Employer branding (21)
Employer resources (155)
Events (120427)
Executive appointments (1011)
FDA (20031)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1499)
Gene editing (207)
Generative AI (46)
Gene therapy (620)
GLP-1 (1016)
Government (4811)
Grass and pollen (7)
Guidances (385)
Healthcare (19068)
HIV (62)
Huntington's disease (46)
IgA nephropathy (86)
Immunology and inflammation (266)
Immuno-oncology (62)
Indications (122)
Infectious disease (3067)
Inflammatory bowel disease (202)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (260)
Interviews (327)
IPO (16921)
IRA (57)
Job creations (4070)
Job search strategy (1500)
JPM (64)
Kidney cancer (16)
Labor market (86)
Layoffs (576)
Leadership (34)
Legal (8425)
Liver cancer (92)
Longevity (16)
Lung cancer (668)
Lymphoma (385)
Machine learning (43)
Management (60)
Manufacturing (837)
MASH (171)
Medical device (13866)
Medtech (13924)
Mergers & acquisitions (20918)
Metabolic disorders (1314)
Multiple sclerosis (164)
NASH (17)
Neurodegenerative disease (330)
Neuropsychiatric disorders (93)
Neuroscience (2981)
Neurotech (1)
NextGen: Class of 2026 (6644)
Non-profit (4563)
Now hiring (68)
Obesity (621)
Opinion (289)
Ovarian cancer (168)
Pain (219)
Pancreatic cancer (234)
Parkinson's disease (287)
Partnered (34)
Patents (517)
Patient recruitment (503)
Peanut (61)
People (60968)
Pharmaceutical (90)
Pharmacy benefit managers (32)
Phase 1 (22107)
Phase 2 (31317)
Phase 3 (23464)
Pipeline (5551)
Policy (304)
Postmarket research (2656)
Preclinical (9391)
Press Release (68)
Prostate cancer (242)
Psychedelics (50)
Radiopharmaceuticals (290)
Rare diseases (886)
Real estate (6306)
Recruiting (72)
Regulatory (25475)
Reports (53)
Research institute (2441)
Resumes & cover letters (362)
Rett syndrome (27)
RNA editing (17)
RSV (81)
Schizophrenia (159)
Series A (246)
Series B (194)
Service/supplier (11)
Sickle cell disease (101)
Special edition (25)
Spinal muscular atrophy (160)
Sponsored (43)
Startups (3766)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (96)
The Weekly (78)
Vaccines (1043)
Venture capital (91)
Weight loss (407)
Women's health (97)
Worklife (18)
Date
Today (129)
Last 7 days (686)
Last 30 days (2404)
Last 365 days (30368)
2026 (4203)
2025 (30680)
2024 (35768)
2023 (40629)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47398)
2018 (35771)
2017 (33136)
2016 (32663)
2015 (38616)
2014 (32516)
2013 (27632)
2012 (29730)
2011 (30489)
2010 (28499)
Location
Africa (800)
Alabama (85)
Alaska (7)
Arizona (319)
Arkansas (15)
Asia (42177)
Australia (6754)
California (11506)
Canada (3345)
China (1146)
Colorado (485)
Connecticut (487)
Delaware (345)
Europe (90467)
Florida (1726)
Georgia (362)
Hawaii (3)
Idaho (61)
Illinois (890)
India (73)
Indiana (539)
Iowa (22)
Japan (448)
Kansas (127)
Kentucky (40)
Louisiana (26)
Maine (72)
Maryland (1410)
Massachusetts (8277)
Michigan (331)
Minnesota (635)
Mississippi (5)
Missouri (129)
Montana (32)
Nebraska (28)
Nevada (125)
New Hampshire (79)
New Jersey (3059)
New Mexico (29)
New York (3030)
North Carolina (1496)
North Dakota (8)
Northern California (5621)
Ohio (340)
Oklahoma (22)
Oregon (46)
Pennsylvania (2326)
Puerto Rico (24)
Rhode Island (48)
South America (1175)
South Carolina (69)
South Dakota (1)
Southern California (4487)
Tennessee (177)
Texas (1772)
United States (40885)
Utah (343)
Vermont (1)
Virginia (281)
Washington D.C. (81)
Washington State (939)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
742,557 Results for "cumberland pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Cumberland Pharmaceuticals to Announce First Quarter 2024 Financial Results
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
April 30, 2024
·
2 min read
Business
Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024.
May 7, 2024
·
21 min read
Business
Cumberland Pharmaceuticals to Announce Annual 2023 Financial Results
Cumberland Pharmaceuticals Inc., a specialty pharmaceuticals company, announced that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.
February 27, 2024
·
2 min read
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $40 million in 2023 and provided $6 million in cash generated from operations.
March 5, 2024
·
24 min read
Business
Cumberland Pharmaceuticals to Announce Third Quarter 2023 Financial Results
Cumberland Pharmaceuticals Inc., a specialty pharmaceuticals company, announced that it will release the third quarter 2023 financial results and provide a company update after the market closes on Tuesday, Nov. 7, 2023.
October 31, 2023
·
2 min read
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $10.1 million during the third quarter of 2023 and $30.2 million year to date.
November 7, 2023
·
24 min read
BioMidwest
Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility
Inotiv Inc. announced that it reached an agreement with the U.S. Department of Justice to resolve a previously-announced criminal investigation into the shuttered canine breeding facility located in Cumberland, Virginia, which was operated originally by Envigo RMS LLC, a company acquired by Inotiv in November 2021.
June 3, 2024
·
5 min read
Business
Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced significantly improved financial results and a favorable overall company performance for the second quarter of 2023.
August 8, 2023
·
24 min read
Business
Cumberland Pharmaceuticals to Announce Second Quarter 2023 Financial Results
Cumberland Pharmaceuticals Inc., a specialty pharmaceuticals company, announced that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023.
August 1, 2023
·
2 min read
Press Releases
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
February 13, 2026
·
12 min read
1 of 74,256
Next
